Total Payments
$1.8M
2024 Payments
$263,242
Companies
58
Transactions
2,721
Medicare Patients
55,647
Medicare Billing
$2.5M
Payment Breakdown by Category
Other$1.4M (78.2%)
Travel$178,413 (10.1%)
Consulting$150,054 (8.5%)
Food & Beverage$53,656 (3.0%)
Research$4,145 (0.2%)
Education$615.20 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 560 | 77.6% |
| Travel and Lodging | $178,413 | 519 | 10.1% |
| Consulting Fee | $150,054 | 60 | 8.5% |
| Food and Beverage | $53,656 | 1,554 | 3.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,875 | 5 | 0.3% |
| Unspecified | $4,145 | 1 | 0.2% |
| Honoraria | $3,795 | 2 | 0.2% |
| Education | $615.20 | 19 | 0.0% |
| Entertainment | $50.22 | 1 | 0.0% |
Payments by Type
General
$1.8M
2,720 transactions
Research
$4,145
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $740,018 | 634 | $0 (2024) |
| Amgen Inc. | $308,241 | 406 | $0 (2024) |
| Amarin Pharma Inc. | $134,273 | 177 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $111,098 | 199 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $84,096 | 129 | $0 (2024) |
| Esperion Therapeutics, Inc. | $75,641 | 123 | $0 (2024) |
| Lilly USA, LLC | $64,688 | 69 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $55,364 | 137 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $46,537 | 73 | $0 (2024) |
| Novo Nordisk Inc | $44,782 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $263,242 | 403 | Amgen Inc. ($66,087) |
| 2023 | $158,223 | 295 | Amgen Inc. ($56,531) |
| 2022 | $185,869 | 325 | Janssen Pharmaceuticals, Inc ($94,565) |
| 2021 | $180,866 | 247 | Janssen Pharmaceuticals, Inc ($100,085) |
| 2020 | $174,348 | 180 | Janssen Pharmaceuticals, Inc ($96,002) |
| 2019 | $254,352 | 397 | Janssen Pharmaceuticals, Inc ($100,815) |
| 2018 | $277,632 | 429 | Janssen Pharmaceuticals, Inc ($107,636) |
| 2017 | $278,765 | 445 | Janssen Pharmaceuticals, Inc ($160,512) |
All Payment Transactions
2,721 individual payment records from CMS Open Payments — Page 1 of 109
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Cardiology | ||||||
| 12/23/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Cardiology | ||||||
| 12/19/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | In-kind items and services | $905.76 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Janssen Global Services, LLC | — | Food and Beverage | Cash or cash equivalent | $60.46 | General |
| 12/18/2024 | Janssen Global Services, LLC | — | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| 12/18/2024 | Janssen Global Services, LLC | — | Travel and Lodging | Cash or cash equivalent | $26.80 | General |
| 12/18/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $20.81 | General |
| Category: Medical Device | ||||||
| 12/17/2024 | Medtronic, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/17/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $124.09 | General |
| Category: Cardiology | ||||||
| 12/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/17/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $2.60 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 12/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $22.87 | General |
| Category: Cardio-renal | ||||||
| 12/12/2024 | Philips North America LLC | (CM9) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $17.80 | General |
| Category: Medical Device | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $12.10 | General |
| Category: Cardiovascular | ||||||
| 12/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,040.00 | General |
| Category: DIABETES | ||||||
| 12/11/2024 | Medtronic, Inc. | ONYX FRONTIER (Device) | Food and Beverage | In-kind items and services | $80.72 | General |
| Category: Stents | ||||||
| 12/11/2024 | Medtronic, Inc. | ONYX FRONTIER (Device) | Food and Beverage | In-kind items and services | $74.00 | General |
| Category: Stents | ||||||
| 12/11/2024 | Medtronic, Inc. | ONYX FRONTIER (Device) | Food and Beverage | In-kind items and services | $47.45 | General |
| Category: Stents | ||||||
| 12/10/2024 | Medtronic, Inc. | ONYX FRONTIER (Device) | Food and Beverage | In-kind items and services | $4.74 | General |
| Category: Stents | ||||||
| 12/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: Cardio-renal | ||||||
| 12/06/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $29.70 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/06/2024 | Medtronic, Inc. | SYMPLICITY G3 (Device) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Renal Denervation System | ||||||
| 12/05/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $29.62 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $5.25 | General |
| Category: Cardiovascular | ||||||
| 12/04/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,040.00 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Review Article | Novartis Pharmaceuticals Corporation | $4,145 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 45 | 12,860 | 25,660 | $2.3M | $612,542 |
| 2022 | 45 | 13,253 | 17,536 | $2.3M | $555,077 |
| 2021 | 48 | 14,750 | 20,402 | $2.5M | $656,413 |
| 2020 | 47 | 14,784 | 20,298 | $2.5M | $630,653 |
Total Patients
55,647
Total Services
83,896
Medicare Billing
$2.5M
Procedure Codes
194
All Medicare Procedures & Services
194 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 1,731 | 2,423 | $836,055 | $193,907 | 23.2% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 18 | 9,088 | $118,144 | $85,191 | 72.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 756 | 762 | $203,554 | $37,854 | 18.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 284 | 284 | $127,516 | $28,954 | 22.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 206 | 240 | $106,548 | $28,371 | 26.6% |
| 83880 | Natriuretic peptide (heart and blood vessel protein) level | Office | 2023 | 453 | 600 | $69,056 | $23,082 | 33.4% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 402 | 402 | $113,681 | $22,055 | 19.4% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 737 | 752 | $62,708 | $19,863 | 31.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 160 | 315 | $61,110 | $18,649 | 30.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 1,267 | 1,753 | $28,048 | $14,649 | 52.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,355 | 1,605 | $96,300 | $14,642 | 15.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 276 | 279 | $54,126 | $14,379 | 26.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 911 | 1,055 | $58,025 | $13,836 | 23.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 105 | 106 | $52,744 | $13,802 | 26.2% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 1,045 | 1,244 | $43,540 | $12,865 | 29.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 84 | $23,436 | $7,595 | 32.4% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 437 | 437 | $43,700 | $6,551 | 15.0% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 297 | 311 | $21,459 | $5,119 | 23.9% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 54 | 55 | $25,410 | $4,415 | 17.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 437 | 437 | $32,775 | $4,363 | 13.3% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 23 | 152 | $10,944 | $3,691 | 33.7% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 150 | 151 | $14,647 | $3,651 | 24.9% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 43 | 530 | $18,020 | $3,650 | 20.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 426 | 470 | $15,040 | $3,577 | 23.8% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 40 | 40 | $11,760 | $3,166 | 26.9% |
About Dr. Dharmesh Patel, MD
Dr. Dharmesh Patel, MD is a Cardiovascular Disease healthcare provider based in Southaven, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2005. The National Provider Identifier (NPI) number assigned to this provider is 1689651036.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dharmesh Patel, MD has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $263,242 received in 2024. These payments were reported across 2,721 transactions from 58 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.4M).
As a Medicare-enrolled provider, Patel has provided services to 55,647 Medicare beneficiaries, totaling 83,896 services with total Medicare billing of $2.5M. Data is available for 4 years (2020–2023), covering 194 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Southaven, MS
- Active Since 12/28/2005
- Last Updated 06/12/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1689651036
Products in Payments
- XARELTO (Drug) $738,334
- Repatha (Biological) $294,401
- JARDIANCE (Drug) $140,897
- Vascepa (Drug) $134,273
- ENTRESTO (Drug) $101,114
- NEXLIZET (Drug) $69,581
- FARXIGA (Drug) $51,743
- Livalo (Drug) $46,516
- Kerendia (Drug) $30,981
- SYMPLICITY G3 (Device) $16,576
- Wegovy (Drug) $11,927
- LEQVIO (Drug) $9,483
- PRADAXA (Drug) $6,327
- NEXLETOL (Drug) $6,060
- ELIQUIS (Drug) $6,060
- XIFAXAN (Drug) $5,875
- Bidil (Drug) $5,227
- Ozempic (Drug) $4,671
- LOKELMA (Drug) $2,925
- PRALUENT ALIROCUMAB INJECTION (Biological) $2,742
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.